DekaBank Deutsche Girozentrale’s UroGen Pharma URGN Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,700	Closed	-$128K	–	1485
2021 Q3	$128K	Hold	7,700	–	–	﹤0.01%	1272
2021 Q2	$119K	Hold	7,700	–	–	﹤0.01%	1310
2021 Q1	$140K	Hold	7,700	–	–	﹤0.01%	1248
2020 Q4	$132K	Hold	7,700	–	–	﹤0.01%	1245
2020 Q3	$145K	Buy	+7,700	New	+$174K	﹤0.01%	1090

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

HCM

Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

DekaBank Deutsche Girozentrale's URGN Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of UroGen Pharma (URGN) in Q4 2021, closing a stake of 7,700 shares — an estimated $128K sold.

DekaBank Deutsche Girozentrale first reported a position in URGN in Q3 2020 and held it in 5 quarters. The position peaked at $145K in Q3 2020. 77 funds tracked by Wall St. Rank hold URGN as of Q4 2021.

DekaBank Deutsche Girozentrale reported no remaining UroGen Pharma position as of Q4 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 7,700 UroGen Pharma shares in Q4 2021, an estimated $128K.
DekaBank Deutsche Girozentrale first reported a position in UroGen Pharma in Q3 2020 and held it in 5 quarters.
DekaBank Deutsche Girozentrale's UroGen Pharma position peaked at $145K in Q3 2020.
77 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.